Physician profile
Larry Cohen
NPI 1295731305
$12,292.91
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,798 · 2020: $346 · 2021: $227 · 2022: $594 · 2023: $2,779 · 2024: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,830 · Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,829.81 |
| Food and Beverage | $1,497.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $7,559.14 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $2,167.05 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| Cvrx, INC. | $516.67 | 2023-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $314.41 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $302.12 | 2019-2024 | Verquvo |
| Amgen INC. | $255.50 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $201.79 | 2019-2024 | Breztri, Wainua |
| Pfizer INC. | $160.39 | 2019-2024 | |
| Novo Nordisk INC | $147.50 | 2019-2024 | Wegovy |
| Allergan, INC. | $124.19 | 2019 | |
| Abbott Laboratories | $98.55 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.29 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $55.64 | 2019-2021 | |
| Heartflow, INC. | $41.63 | 2024 | |
| Lilly USA, LLC | $40.35 | 2019-2023 | Mounjaro, Trulicity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $36.76 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $30.00 | 2024 | Edarbi |
| Esperion Therapeutics, INC. | $28.93 | 2021-2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $27.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.89 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.69 | 2019-2021 | |
| Biotronik INC. | $15.76 | 2019 | |
| Daiichi Sankyo INC. | $14.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.